Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 1/2018

01-02-2018 | Review

Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies

Authors: Yoori Choi, Seunggyun Ha, Yun-Sang Lee, Yun Kyung Kim, Dong Soo Lee, Dong Jin Kim

Published in: Nuclear Medicine and Molecular Imaging | Issue 1/2018

Login to get access

Abstract

The pathological features of Alzheimer’s disease are senile plaques which are aggregates of β-amyloid peptides and neurofibrillary tangles in the brain. Neurofibrillary tangles are aggregates of hyperphosphorylated tau proteins, and these induce various other neurodegenerative diseases, such as progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobar degeneration, frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and chronic traumatic encephalopathy. In the case of Alzheimer’s disease, the measurement of neurofibrillary tangles associated with cognitive decline is suitable for differential diagnosis, disease progression assessment, and to monitor the effects of therapeutic treatment. This review discusses considerations for the development of tau ligands for imaging and summarizes the results of the first-in-human and preclinical studies of the tau tracers that have been developed thus far. The development of tau ligands for imaging studies will be helpful for differential diagnosis and for the development of therapeutic treatments for tauopathies including Alzheimer’s disease.
Literature
1.
2.
Kolarova M, Garcia-Sierra F, Bartos A, Ricny J, Ripova D. Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers dis. 2012;2012:731526.PubMedPubMedCentral
3.
Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, et al. Tau protein kinases: involvement in Alzheimer’s disease. Ageing res rev. 2013;12:289–309.CrossRefPubMed
4.
Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271–8.CrossRefPubMed
5.
Delacourte A. Biochemical and molecular characterization of neurofibrillary degeneration in frontotemporal dementias. Dement Geriatr Cogn Disord. 1999;10:75–9.CrossRefPubMed
6.
McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol. 2009;68:709–35.CrossRefPubMedPubMedCentral
7.
8.
Delacourte A. Tauopathies: recent insights into old diseases. Folia Neuropathol. 2005;43:244–57.PubMed
9.
10.
11.
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, et al. 2014 update of the Alzheimer’s disease neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2015;11:e1–120.CrossRefPubMedPubMedCentral
12.
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, et al. Impact of the Alzheimer’s disease neuroimaging Initiative, 2004 to 2014. Alzheimers Dement. 2015;11:865–84.CrossRefPubMedPubMedCentral
13.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92.CrossRefPubMedPubMedCentral
14.
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9.CrossRefPubMedPubMedCentral
15.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.CrossRefPubMedPubMedCentral
16.
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306–19.CrossRefPubMed
17.
Cselenyi Z, Jonhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med. 2012;53:415–24.CrossRefPubMed
18.
Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18). J Nucl Med. 2010;51:913–20.CrossRefPubMedPubMedCentral
19.
Barthel H, Gertz H-J, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35.CrossRefPubMed
20.
Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.CrossRefPubMed
21.
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42:631–9.CrossRefPubMed
22.
Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003;60:729–36.CrossRefPubMed
23.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292–323.CrossRefPubMed
24.
Barghorn S, Mandelkow E. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry. 2002;41:14885–96.CrossRefPubMed
25.
Gamblin TC, King ME, Dawson H, Vitek MP, Kuret J, Berry RW, et al. In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. Biochemistry. 2000;39:6136–44.CrossRefPubMed
26.
King ME, Ahuja V, Binder LI, Kuret J. Ligand-dependent tau filament formation: implications for Alzheimer’s disease progression. Biochemistry. 1999;38:14851–9.CrossRefPubMed
27.
Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain. 2011;134:1089–100.CrossRefPubMed
28.
Lim S, Haque MM, Su D, Kim D, Lee J-S, Chang Y-T, et al. Development of a BODIPY-based fluorescent probe for imaging pathological tau aggregates in live cells. Chem Commun. 2017;53:1607–10.CrossRef
29.
Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420–7.CrossRefPubMed
30.
31.
32.
Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer’s disease. Neurochem Int. 2011;58:458–71.CrossRefPubMed
33.
Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci. 2015;16:109–20.CrossRefPubMedPubMedCentral
34.
Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer’s disease. J Alzheimers Dis. 2010;19:573–89.CrossRefPubMedPubMedCentral
35.
Schafer KN, Kim S, Matzavinos A, Kuret J. Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer’s disease: a simulation study. NeuroImage. 2012;60:1724–33.CrossRefPubMed
36.
Agdeppa EDKV, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, et al. Binding characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer’s disease. J Neurosci. 2001;21:RC189.PubMed
37.
Shin J, Lee SY, Kim SH, Kim YB, Cho SJ. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer’s disease. NeuroImage. 2008;43:236–44.CrossRefPubMed
38.
Braskie MN, Klunder AD, Hayashi KM, Protas H, Kepe V, Miller KJ, et al. Plaque and tangle imaging and cognition in normal aging and Alzheimer’s disease. Neurobiol Aging. 2010;31:1669–78.CrossRefPubMed
39.
Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J med. 2006;355:2652–63.CrossRefPubMed
40.
Nelson LD, Siddarth P, Kepe V, Scheibel KE, Huang SC, Barrio JR, et al. Positron emission tomography of brain beta-amyloid and tau levels in adults with down syndrome. Arch Neurol. 2011;68:768–74.CrossRefPubMedPubMedCentral
41.
Barrio JRSG, Wong KP, Huang SC, Liu J, Merrill DA, Giza CC, et al. In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging. Proc Natl Acad Sci U S A. 2015;112:E2039–47.CrossRefPubMedPubMedCentral
42.
Kepe V, Bordelon Y, Boxer A, Huang SC, Liu J, Thiede FC, et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers dis. 2013;36:145–53.PubMedPubMedCentral
43.
Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208–14.CrossRefPubMed
44.
Fodero-Tavoletti MT, Furumoto S, Taylor L, McLean CA, Mulligan RS, Birchall I, et al. Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non-Alzheimer’s disease tauopathies. Alzheimers Res Ther. 2014;6:11.CrossRefPubMedPubMedCentral
45.
Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114–24.CrossRefPubMed
46.
Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137:1762–71.CrossRefPubMed
47.
Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539–50.CrossRefPubMed
48.
Tago T, Furumoto S, Okamura N, Harada R, Adachi H, Ishikawa Y, et al. Preclinical evaluation of [(18)F]THK-5105 enantiomers: effects of chirality on its effectiveness as a tau imaging radiotracer. Mol Imaging Biol. 2016;18:258–66.CrossRefPubMed
49.
Brendel M, Jaworska A, Probst F, Overhoff F, Korzhova V, Lindner S, et al. Small-animal PET imaging of tau pathology with 18F-THK5117 in 2 transgenic mouse models. J Nucl Med. 2016;57:792–8.CrossRefPubMed
50.
Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, et al. A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis. 2012;31:601–12.PubMed
51.
Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement. 2013;9:666–76.CrossRefPubMed
52.
Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457–68.PubMed
53.
Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171–84.PubMed
54.
Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, et al. Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between beta-amyloid and Tauopathy. JAMA Neurol. 2016;73:1070–7.CrossRefPubMedPubMedCentral
55.
Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80:247–58.CrossRefPubMed
56.
Scholl M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971–82.CrossRefPubMedPubMedCentral
57.
WashingtonUniversity. F 18 T807 Tau PET imaging of Alzheimer’s disease. ClinicalTrialsgov Identifier: NCT02414347. 2015.
58.
Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094–108.CrossRefPubMed
59.
Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–67.CrossRefPubMedPubMedCentral
60.
Lockhart SN, Baker SL, Okamura N, Furukawa K, Ishiki A, Furumoto S, et al. Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer’s disease patients measured using [18F] THK-5351. PLoS One. 2016;11:e0158460.CrossRefPubMedPubMedCentral
61.
Betthauser T, Lao PJ, Murali D, Barnhart TE, Furumoto S, Okamura N et al. In vivo comparison of tau radioligands 18F–THK-5351 and 18F–THK-5317. J Nucl Med. 2016.
62.
Roche. Evaluation of [18F]RO6958948 as tracer for positron emission tomography (PET) imaging of Tau Burden in Alzheimer’s disease participants. ClinicalTrialsgov Identifier: NCT02792179. 2016.
63.
Shao X, Carpenter GM, Desmond TJ, Sherman P, Quesada CA, Fawaz M, et al. Evaluation of [(11)C]N-methyl lansoprazole as a radiopharmaceutical for PET imaging of tau neurofibrillary tangles. ACS Med Chem Lett. 2012;3:936–41.CrossRefPubMedPubMedCentral
64.
Fawaz MV, Brooks AF, Rodnick ME, Carpenter GM, Shao X, Desmond TJ, et al. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer’s disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. ACS Chem Neurosci. 2014;5:718–30.CrossRefPubMedPubMedCentral
65.
Walji AM, Hostetler ED, Selnick H, Zeng Z, Miller P, Bennacef I, et al. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59:4778–89.CrossRefPubMed
66.
Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57:1599–606.CrossRefPubMed
67.
Genentech. Longitudinal evaluation of [18F]MNI-798 as a PET radioligand for imaging Tau in the brain of patients with Alzheimer’s disease compared to healthy volunteers. ClinicalTrialsgov Identifier: NCT02640092. 2015.
Metadata
Title
Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies
Authors
Yoori Choi
Seunggyun Ha
Yun-Sang Lee
Yun Kyung Kim
Dong Soo Lee
Dong Jin Kim
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 1/2018
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-017-0484-7

Other articles of this Issue 1/2018

Nuclear Medicine and Molecular Imaging 1/2018 Go to the issue

Perspective

PERCIST in Perspective

Original Article

The Utility of FDG PET/CT in IgG4-Related Disease with a Focus on Coronary Artery Involvement

Interesting Image

Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept

Case Report

Systemic Lupus Erythematosus Associated Pitfalls on 18F-FDG PET/CT: Reactive Follicular Hyperplasia, Kikuchi-Fujimoto Disease, Inflammation and Lymphoid Hyperplasia of the Spleen Mimicking Lymphoma

Review

Obesity and Brain Positron Emission Tomography

Review

Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?